Enbrel for psoriatic arthritis
Executive Summary
FDA has told Immunex that there are no issues that would require an advisory committee review related to the use of Enbrel (etanercept) for the treatment of psoriatic arthritis, company says. Immunex previously expected a committee review in December (1"The Pink Sheet" Oct. 29, p. 27). The Arthritis Advisory Committee will meet in closed session on Dec. 7 to discuss trade secret information...